• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SI-BONE To Report Third Quarter 2024 Financial Results on November 12, 2024

    10/22/24 4:09:00 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care
    Get the next $SIBN alert in real time by email

    SANTA CLARA, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

    Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/b8oqnu9r. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

    About SI-BONE, Inc.

    SI-BONE (NASDAQ:SIBN) is a global leader in technology for the surgical treatment of sacropelvic disorders. Since pioneering minimally invasive surgery of the SI joint in 2009, SI-BONE has supported over 3,900 surgeons in performing more than 100,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including two randomized controlled trials and over 135 peer-reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation, and pelvic trauma.

    For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

    iFuse Bedrock Granite, iFuse-TORQ, iFuse TORQ TNT, SI-BONE, and iFuse INTRA are registered trademarks of SI-BONE, Inc. ©2024 SI-BONE, Inc. All Rights Reserved.

    Investor Contact: Saqib Iqbal [email protected]



    Primary Logo

    Get the next $SIBN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SIBN

    DatePrice TargetRatingAnalyst
    8/6/2024$27.00 → $19.00Buy
    Needham
    3/28/2024$25.00Overweight
    Piper Sandler
    10/12/2022$20.00Buy
    Jefferies
    4/7/2022$34.00Overweight
    Cantor Fitzgerald
    3/1/2022$30.00 → $28.00Overweight
    Morgan Stanley
    1/18/2022$43.00 → $36.00Buy
    B of A Securities
    12/21/2021$35.00 → $30.00Buy
    Truist Securities
    11/9/2021$42.00 → $36.00Market Outperform
    JMP Securities
    More analyst ratings

    $SIBN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Dunn Jeffrey W was granted 8,675 shares and sold $64,335 worth of shares (3,377 units at $19.05), increasing direct ownership by 38% to 17,354 units (SEC Form 4)

      4 - SI-BONE, Inc. (0001459839) (Issuer)

      6/6/25 7:48:03 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Director West Thomas A. was granted 8,675 shares, increasing direct ownership by 47% to 26,990 units (SEC Form 4)

      4 - SI-BONE, Inc. (0001459839) (Issuer)

      6/6/25 7:46:55 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care
    • Director Nishimura Mika was granted 8,675 shares, increasing direct ownership by 31% to 36,816 units (SEC Form 4)

      4 - SI-BONE, Inc. (0001459839) (Issuer)

      6/6/25 7:46:15 PM ET
      $SIBN
      Medical/Dental Instruments
      Health Care